2010 Annual Meeting | Clinical Issues in Multiple Sclerosis
09:00 AM - 09:15 AM |
Debate: Argument For: Resolved That MS Can Be Reliably Diagnosed in Presymptomatic Individuals
Brian G. Weinshenker, MD, FAAN |
|
09:15 AM - 09:30 AM |
Debate: Argument Against: Resolved That MS Can Be Reliably Diagnosed in Presymptomatic Individuals
Paul W. O'Connor, MD |
|
09:30 AM - 09:50 AM |
Rebuttals and Summary
|
|
09:50 AM - 10:05 AM |
Management of Fatigue in MS: Should We Use Stimulants or Alternative Treatments First?
Dean M. Wingerchuk, MD, FAAN |
|
10:05 AM - 10:20 AM |
Debate: Argument For: Resolved That Immunotherapy Is Not Beneficial for Patients With Progressive Forms of MS and It Is Inappropriate to Prescribe Such Therapy
Alasdair Coles, MD, PhD |
|
10:20 AM - 10:35 AM |
Debate: Argument Against: Resolved That Immunotherapy Is Not Beneficial for Patients With Progressive Forms of MS and It Is Inappropriate to Prescribe Such Therapy
Dean M. Wingerchuk, MD, FAAN |
|
10:35 AM - 10:55 AM |
Rebuttals and Summary
|
|
10:55 AM - 11:10 AM |
Break
|
|
11:10 AM - 11:25 AM |
Role of Vitamin D in MS Causation/Pathogenesis: Important Etiological Factor or Oversimplified Explanation of the Latitudinal Gradient?
Paul W. O'Connor, MD |
|
11:25 AM - 11:40 AM |
Risks of Mitoxantrone: Are the Risks of Leukemia and Cardiotoxicity Justified?
Alasdair Coles, MD, PhD |
|
11:40 AM - 12:45 PM |
Interactive Case Discussions: Diagnostic Difficulties, Early Management Controversies, and Treatment of Refractory Cases
Brian G. Weinshenker, MD, FAAN, Dean M. Wingerchuk, MD, FAAN |
Brian G. Weinshenker, MD, FAAN | Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. The institution of Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a speaker at internal meeting and symposium with Horizon. |
Dean M. Wingerchuk, MD, FAAN | Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers. |
Paul W. O'Connor, MD | No disclosure on file |
Alasdair Coles, MD, PhD | Dr. Coles has nothing to disclose. |